FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB	APPROVAL
UIVID	APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

1. Name and Address of Reporting Person* CREDIT SUISSE FIRST BOSTON/							2. Issuer Name and Ticker or Trading Symbol XCYTE THERAPIES INC [XCYT]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(Last) ELEVEN	,	irst) N AVENUE	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/19/2004 Officer (give title below)									itie	Other (specify below)			
(Street) NEW YORK NY 10010							4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person												
(City)	(Si	tate)	(Zip)																
		Т	able I - I	Non-D	erivat	tive	Secu	ırities A	cquire	ed, C	Disposed	of, or B	eneficial	ly Owned					
1. Title of Security (Instr. 3)			2. Trans Date (Month	saction /Day/Ye	ar) E	f any	emed ion Date, /Day/Year)	3. Transa Code (8)		4. Securitie Disposed C		(A) or 3, 4 and 5)	5. Amount of Securities Beneficially Owned Foll Reported	, owing	6. Own Form: I (D) or I (I) (Inst	Direct ndirect	7. Nature Indirect Benefici Ownersi 4)		
						_			Code	V	Amount	(A) or (D)	Price	Transaction (Instr. 3 and	ı(s) I 4)				
Common	Stock			03/1	9/2004	4			С		10,670	A	\$0	0	I		I		otes ⁽¹⁾⁽²⁾
Common	Stock			03/1	9/2004	4			С		478,466	478,466 A		0		I See Footno		otes ⁽¹⁾⁽³⁾	
Common	Stock			03/1	9/2004	4			С		99,172	. A \$0		0		1 1		See Footno	otes ⁽¹⁾⁽⁴⁾
Common	Stock			03/1	9/2004	004		С		207,805	5 A	\$0	0				See Footno	otes ⁽¹⁾⁽⁵⁾	
Common	Common Stock 03/19/20			9/2004	004			С		58,861	,861 A S		0	0		I See Footnotes ⁽¹⁾⁽⁶⁾			
Common	Common Stock 03/19/20			9/2004	04			С		64,741 A		\$0	0	0		I See Footnotes ⁽¹⁾⁽⁷⁾		otes ⁽¹⁾⁽⁷⁾	
Common Stock 03/19/20			9/2004	004			С		660	A	\$0	0				See Footno	otes ⁽¹⁾⁽⁸⁾		
Common Stock 03/19/20			9/2004	104			С		35,360	A	\$0	0		:	I	See Footno	otes ⁽¹⁾⁽⁹⁾		
Common Stock 03/19/			9/2004	2004 C 5,229 A \$0 960,964				64	I See Footnotes ⁽¹⁾⁽¹⁰⁾										
			Table	ll - Dei (e.ç	rivativ J., put	re Se ts, ca	ecuri alls,	ities Ac warran	quired ts, opt	l, Di	sposed o	f, or Ber	neficially urities)	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (8)	5. Number of Derivative		6. Date Exerci Expiration Da		Expiration Date (Month/Day/Year)		d Amount ies g Security nd 4)	8. Price of Derivative Security (Instr. 5) Bene Own Follo Repo		ities Form: icially Direct (E d or Indire ving (I) (Instr.		D) Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4	1)			
Convertible Promissory Note	\$9.625	03/19/2004		С				10,670	(12))	03/19/2004	Common Stock	10,670	\$9.625	()	I	See Foo	otnotes ⁽¹⁾⁽²⁾
Series A Convertible Preferred Stock	(11)	03/19/2004		С			478,466		(12))	03/19/2004	Common Stock	478,466	\$5.225	(0		See Foo	otnotes ⁽¹⁾⁽³⁾
Series B Convertible Preeferred Stock	(11)	03/19/2004		С				99,172)	03/19/2004	Common Stock	99,172	\$6.05	()	I	See Foo	otnotes ⁽¹⁾⁽⁴⁾
Series C Convertible Preferred Stock	(11)	03/19/2004			С		207,805		(12))	03/19/2004	Common Stock	207,805	\$9.185	()	I	See Foo	otnotes ⁽¹⁾⁽⁵⁾
Series D Convertible Preferred Stock	(11)	03/19/2004		С			58,861		(12))	03/19/2004	Common Stock	58,861	\$15.29	()	I	See Foo	otnotes ⁽¹⁾⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date (Month/Day/Year)		and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
								Date			Amount or		Transaction(s) (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Number of Shares						
Series E Convertible Preferred Stock	(11)	03/19/2004		С			64,741	(12)	03/19/2004	Common Stock	64,741	\$15.29	0	I	See Footnotes ⁽¹⁾⁽⁷⁾		
Series F Convertible Preferred Stock	(11)	03/19/2004		С			660	(12)	03/19/2004	Common Stock	660	\$15.29	0	I	See Footnotes ⁽¹⁾⁽⁸⁾		
Common Stock Warrants (Right to Buy)	\$0.055	03/19/2004		x			35,360	(12)	03/19/2004	Common Stock	35,360	\$0.055	0	I	See Footnotes ⁽¹⁾⁽⁹⁾		
Common Stock Warrants (Right to Buy)	\$1.65	03/19/2004		х			5,229	(12)	03/19/2004	Common Stock	5,229	\$1.65	0	I	See Footnotes ⁽¹⁾⁽¹⁰⁾		

Explanation of Responses:

- 1. See Attachment
- 2. See Attachment
- 3. See Attachment
- 4. See Attachment
- 5. See Attachment
- 6. See Attachment
- 7. See Attachment
- 8. See Attachment
- 9. See Attachment
- 10. See Attachment
- 11. 1-for-1
- 12. Immediately

/s/ Ivy Dodes, on behalf of Credit Suisse First Boston

03/23/2004

<u>business unit</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Reporting Person	Issuer Name and Ticker Symbol Statement for MM/DD/YY
Credit Suisse First Boston, on behalf of the Credit Suisse First Boston business unit (1) Eleven Madison Avenue	Xcyte Therapies, Inc. (XCYT) 3/19/04

Attachment A

EXPLANATION TO RESPONSES:

New York, New York 10010

(1) In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Form 4 is being filed by Credit Suisse First Boston (the "Bank"), a Swiss bank, on behalf of itself and its subsidiaries, to the extent that they constitute the Credit Suisse First Boston business unit (the "CSFB business unit") excluding Asset Management (as defined below) (the "Reporting Person"). The CSFB business unit is also comprised of an asset management business principally conducted under the brand name Credit Suisse Asset Management ("Asset Management"). The Reporting Person provides financial advisory and capital raising services, sales and trading for users and suppliers of capital around the world and invests in and manages private equity and venture capital funds. Asset Management provides asset management and investment advisory services to institutional, mutual fund and private investors worldwide. The address of the Bank's principal business and office is Uetlibergstrasse 231, P.O. Box 900, CH 8070 Zurich, Switzerland. The address of the Reporting Person's principal business and office in the United States is Eleven Madison Avenue, New York, New York 10010.

The Bank owns directly a majority of the voting stock, and all of the non-voting stock, of Credit Suisse First Boston, Inc. ("CSFBI"), a Delaware corporation. The address of CSFBI's principal business and office is Eleven Madison Avenue, New York, New York 10010. The ultimate parent company of the Bank and CSFBI, and the direct owner of the remainder of the voting stock of CSFBI, is Credit Suisse Group ("CSG"), a corporation formed under the laws of Switzerland. CSFBI owns all of the voting stock of Credit Suisse First Boston (USA), Inc. ("CSFB-USA"), a Delaware corporation and holding company. Credit Suisse First Boston LLC ("CSFB LLC"), a Delaware limited liability company, is a registered broker-dealer and the successor company of Credit Suisse First Boston Corporation ("CSFBC"). CSFB-USA is the sole member of CSFB LLC. The address of the principal business and office of each of CSFB-USA and CSFB LLC is Eleven Madison Avenue, New York, New York 10010.

CSG is a global financial services company with two distinct business units. In addition to the CSFB business unit, CSG and its consolidated subsidiaries are comprised of the Credit Suisse Financial Services business unit. CSG's business address is Paradeplatz 8, P.O. Box 1, CH 8070 Zurich, Switzerland.

CSG, for purposes of the federal securities laws, may be deemed ultimately to control the Bank and the Reporting Person. CSG, its executive officers and directors, and its direct and indirect subsidiaries (including Asset Management and the Credit Suisse

Financial Services business unit) may beneficially own shares of the securities of the issuer to which this Form relates (the "Shares") and such Shares are not reported in this statement. CSG expressly disclaims beneficial ownership of Shares beneficially owned by its direct and indirect subsidiaries, including the Reporting Person. The Reporting Person disclaims beneficial ownership of Shares beneficially owned by CSG, Asset Management and the Credit Suisse Financial Services business unit.

Sprout Capital VII, L.P. ("Sprout VII"), Sprout CEO Fund, L.P. ("Sprout CEO"), DLJ First ESC, L.P. ("ESC") and Sprout Plan Investors, L.P. ("Plan Investors") are Delaware limited partnerships which make investments for long term appreciation. DLJ Capital Corporation ("DLJCC"), a Delaware corporation and a wholly-owned subsidiary of CSFB-USA, acts as a venture capital partnership management company. DLJCC is also the general partner of Sprout CEO and the managing general partner of Sprout VII and, as such, is responsible for their day-to-day management. DLJCC makes all of the investment decisions on behalf of Sprout VII and Sprout CEO. DLJ Associates VII, L.P. ("Associates VII"), a Delaware limited partnership, is a general partner of Sprout VII and in accordance with the terms of the relevant partnership agreement, does not participate in investment decisions made on behalf of Sprout VII. DLJ Capital Associates VII, Inc. ("DLJCA VII"), a Delaware corporation and wholly-owned subsidiary of CSFB-USA, is the

managing general partner of Associates VII. DLJ LBO Plans Management Corporation ("DLJLBO"), a Delaware corporation, is the general partner of ESC and, as such, is responsible for its day-to-day management. DLJLBO makes all of the investment decisions on behalf of ESC. DLJ LBO Plans Management Corporation II ("DLJLBOII"), a Delaware corporation, is the general partner of Plan Investors and, as such, is responsible for its day-to-day management. DLJLBOII makes all of the investment decisions on behalf of Plan Investors. DLJLBO and DLJLBOII are wholly-owned subsidiaries of Credit Suisse First Boston Private Equity, Inc. ("CSFBPE"), a Delaware corporation, which, in turn, is a wholly-owned subsidiary of CSFB-USA. The address of the principal business and office of each of CSFB-USA, DLJCC, Sprout VII, ESC, Sprout CEO and Plan Investors is Eleven Madison Avenue, New York, New York 10010.

- (2) Includes 213 shares of Common Stock, upon conversion of convertible promissory notes held of record by DLJ Capital Corporation, 1,067 shares of Common Stock, upon conversion of convertible promissory notes held of record by Sprout Plan Investors, L.P., 9,283 shares of Common Stock, upon conversion of convertible promissory notes held of record by Sprout Capital VII, L.P. and 107 shares of Common Stock, upon conversion of convertible promissory notes held of record by Sprout CEO Fund, L.P., all of which convertible promissory notes were converted to Common Stock upon the closing of the issuer's initial public offering.
- (3) Includes 9,569 shares of Series A Convertible Preferred Stock held of record by DLJ Capital Corporation., 47,846 shares of Common Stock, upon conversion of Series A Convertible Preferred Stock, held of record by DLJ First ESC., L.P., 416,217 shares of Common Stock, upon conversion of Series A Convertible Preferred Stock, held of record by Sprout Capital VII, L.P., and 4,834 shares of Common Stock, upon conversion of Series A Preferred Convertible Stock, held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering.
- (4) Includes 1,983 shares of Series B Convertible Preferred Stock held of record by DLJ Capital Corporation., 9,917 shares of Series B Convertible Preferred Stock held of record by DLJ First ESC., L.P., 86,270 shares of Series B Convertible Preferred Stock held of record by Sprout Capital VII, L.P., and 1,002 shares of Series B Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering.
- (5) Includes 4,156 shares of Series C Convertible Preferred Stock held of record by DLJ Capital Corporation., 20,780 shares of Series C Convertible Preferred Stock held of record by DLJ First ESC., L.P., 180,770 shares of Series C Convertible Preferred Stock held of record by Sprout Capital VII, L.P., and 2,099 shares of Series C Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering.
- (6) Includes 1,177 shares of Series D Convertible Preferred Stock held of record by DLJ Capital Corporation., 5,886 shares of Series D Convertible Preferred Stock held of record by DLJ First ESC., L.P., 51,204 shares of Series D Convertible Preferred Stock held of record by Sprout Capital VII, L.P., and 594 shares of Series D Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering.
- (7) Includes 1,308 shares of Series E Convertible Preferred Stock held of record by DLJ Capital Corporation., 6,540 shares of Series E Convertible Preferred Stock held of record by DLJ First ESC., L.P., and 56,893 shares of Series E Convertible Preferred Stock held of record by Sprout Capital VII, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering.
- (8) Includes 660 shares of Series F Convertible Preferred Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering.
- (9) Includes 707 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation, 3,535 shares of Common Stock issuable upon exercise of warrants held of record by DLJ First ESC, L.P., 30,762 shares of Common Stock issuable upon exercise of warrants held of record by Sprout Capital VII, L.P. and 356 shares of Common Stock issuable upon the exercise of warrants held of record by Sprout CEO Fund, L.P., all of which

warrants were exercised upon the closing of the issuer's initial public offering through a net exercise feature at the initial public offering price.

(10) Includes 103 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation, 523 shares of Common Stock issuable upon exercise of warrants held of record by DLJ First ESC, L.P., 4,551 shares of Common Stock issuable upon exercise of warrants held of record by Sprout Capital VII, L.P. and 52 shares of Common Stock issuable upon the exercise of warrants held of record by Sprout CEO Fund, L.P., all of which warrants were exercised upon the closing of the issuer's initial public offering through a net exercise feature at the initial public offering price.